WO1997026359A1 - Sistema de expresion de antigenos heterologos como proteinas de fusion - Google Patents
Sistema de expresion de antigenos heterologos como proteinas de fusion Download PDFInfo
- Publication number
- WO1997026359A1 WO1997026359A1 PCT/CU1997/000001 CU9700001W WO9726359A1 WO 1997026359 A1 WO1997026359 A1 WO 1997026359A1 CU 9700001 W CU9700001 W CU 9700001W WO 9726359 A1 WO9726359 A1 WO 9726359A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- sequence
- fusion
- expression
- amino acids
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 40
- 239000000427 antigen Substances 0.000 title claims abstract description 29
- 102000036639 antigens Human genes 0.000 title claims abstract description 29
- 108091007433 antigens Proteins 0.000 title claims abstract description 29
- 102000037865 fusion proteins Human genes 0.000 title claims description 20
- 108020001507 fusion proteins Proteins 0.000 title claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 93
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 79
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 74
- 150000001413 amino acids Chemical class 0.000 claims abstract description 67
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 49
- 229920001184 polypeptide Polymers 0.000 claims abstract description 31
- 241000588724 Escherichia coli Species 0.000 claims abstract description 28
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 27
- 241000588650 Neisseria meningitidis Species 0.000 claims abstract description 19
- 239000012634 fragment Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 18
- 230000004927 fusion Effects 0.000 claims abstract description 15
- 238000010367 cloning Methods 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 229960005486 vaccine Drugs 0.000 claims abstract description 7
- 238000013518 transcription Methods 0.000 claims abstract description 3
- 230000035897 transcription Effects 0.000 claims abstract description 3
- 239000003381 stabilizer Substances 0.000 claims description 36
- 239000013612 plasmid Substances 0.000 claims description 19
- 238000000746 purification Methods 0.000 claims description 12
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 7
- 230000002163 immunogen Effects 0.000 claims description 6
- 101710116435 Outer membrane protein Proteins 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229960000723 ampicillin Drugs 0.000 claims description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 241001646716 Escherichia coli K-12 Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 108700018753 Neisseria porin Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 abstract description 62
- 235000001014 amino acid Nutrition 0.000 abstract description 53
- 230000001580 bacterial effect Effects 0.000 abstract description 5
- 108020004414 DNA Proteins 0.000 abstract description 4
- 241000701533 Escherichia virus T4 Species 0.000 abstract description 4
- 108020004511 Recombinant DNA Proteins 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 description 13
- 102000000588 Interleukin-2 Human genes 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 230000027455 binding Effects 0.000 description 12
- 210000003000 inclusion body Anatomy 0.000 description 12
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 12
- 235000019136 lipoic acid Nutrition 0.000 description 12
- 229960002663 thioctic acid Drugs 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 108010073112 Dihydrolipoyllysine-residue acetyltransferase Proteins 0.000 description 7
- 102000009093 Dihydrolipoyllysine-residue acetyltransferase Human genes 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 229940125575 vaccine candidate Drugs 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 101150093941 PORA gene Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108090000144 Human Proteins Proteins 0.000 description 4
- 102000003839 Human Proteins Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 101800001707 Spacer peptide Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- KNCHTBNNSQSLRV-YFKPBYRVSA-N (2s)-6-amino-2-[(2,2,2-trifluoroacetyl)amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)C(F)(F)F KNCHTBNNSQSLRV-YFKPBYRVSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 102100032534 Adenosine kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000589149 Azotobacter vinelandii Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102400000498 Connective tissue-activating peptide III Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000028526 Dihydrolipoamide Dehydrogenase Human genes 0.000 description 1
- 108010028127 Dihydrolipoamide Dehydrogenase Proteins 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101000757236 Homo sapiens Angiogenin Proteins 0.000 description 1
- 101000674732 Homo sapiens TGF-beta-activated kinase 1 and MAP3K7-binding protein 3 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010051679 Methylmalonyl-CoA carboxytransferase Proteins 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000017033 Porins Human genes 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 1
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100021229 TGF-beta-activated kinase 1 and MAP3K7-binding protein 3 Human genes 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000000782 polymeric membrane extraction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Definitions
- the present invention is related to the branch of biotechnology and genetic engineering, particularly with the expression of heterologous proteins in microbial hosts by fusion, using recombinant DNA technology, to bacterial peptides.
- Intracellular synthesis has been the most used strategy for obtaining heterologous polypeptides in E. coli, due to the high levels of expression attainable (Goeddel, DV, Methods Enzymol., 185, 3-7, 1990).
- factors such as host protease sensitivity or expressed protein toxicity can significantly decrease these levels, regardless of the use of high efficiency regulatory sequences (Lee, CA and Saier, MH, J. Bacteriol., 153, 685 -692; Gwyn, GW, Membrane Pi otein Expression Systems: A User's Guide, Portland Press, London, UK, 29-82).
- Inclusion bodies are insoluble protein aggregates that appear as electrodense bodies in the cytosol during the expression of many recombinant proteins in E. coli (Ri ⁇ as, U. and Bailey, J., Appl. Microbiol. Biotechnol., 37, 609-614 ).
- WO 9207939 A2 920514 of constant regions of immunoglobulins, as described in European Patent Application No. EP 0464533 to 920108; of human angiogenin (European patent application No. EP 0423641 A2 910424), of growth hormone (EP 0429586 Al 910605), glutathione-S-transferase (WO 8809372 Al 881201) and of porcine adenylate kinase (EP 0423641 A2 910424 and EP 0412526 A2 910213).
- stabilizing polypeptides that constitute a significant part of the fusion protein has some disadvantages if the former is a vaccine candidate, since the presence of foreign sequences can alter the natural order of the B and T cell epitopes (Denton , G., Hudecz, F., Kajtár, J. et al, Peptide Research, 7, 258-264) or their processing by antigen presenting cells (Del Val, M., Schlicht, H., Ruppert , T., et al, Cell, 66, 1 145-1 153), and may even seriously affect its immunogenicity by the epitopo-specific suppression phenomenon (Etlinger, H., Immunol. Today, 13, 52 -55).
- German patent application No. 35 41 856 Al reports the possibility of using a stabilizing peptide consisting of at least the first 95 amino acids of the N-terminal end of the human protein Interleukin-2 (IL-2) to obtain fusion proteins insolubly synthesized in E. cali.
- IL-2 Interleukin-2
- European patent applications No. 0 416 673 A2 and No. 229 998 of the same firm a stabilizing peptide consisting of the first 58 or 38 amino acids of said protein is used, respectively.
- the first 58 residues of IL-2 are also used in European Patent No.
- the stabilizing peptide is separated from the protein of interest by a spacer that allows independent folding of both, and whose amino acid sequence makes it susceptible to attack by specific endopeptidases. If there is a ligand that recognizes the chosen stabilizer, it is then possible to purify the fusion polypeptide by affinity chromatography and finally separate it from the stabilizer by treatment with certain proteases (Cress, D., Shultz, J. and Breitlow, S., Promega Notes, 42, 2-7).
- An additional advantage is the possibility of taking advantage of this molecular interaction for the follow-up of intermediate purification steps without the need to have antibodies for each protein to be expressed.
- EP 0131363 Al 850116 or in glutathione-S-transferase (patent application No. EP 0293249 Al 88130, from Amrad Corp., Ltd.) purifiable with substrate matrices immobilized; in Staphylococcus aureus protein A, according to patent application No. WO 9109946 Al 91071 1; and in the 12.5 kDa subunit of the Proprionibacte ⁇ um shermanii transcarboxylase complex, which is biotinylated in vivo and allows purification based on the affinity of biotin for avidin (Cress, D., Shultz, J. and Breitlow, S ., Promega Notes, 42, 2-7, patent applications No. EP 0472658 Al 920304 or WO 9014431 Al 901 129).
- the object of the present invention is a process for the expression at high levels of heterologous proteins as fusion polypeptides in E. coli; which is based on the use of a stabilizing sequence derived from the first 47 amino acids of the P64k antigen of N. meningitidis B: 4: P1.15 (European Patent Application No. 0 474 313 A2) which confers on them the capacity of expressing oneself as inclusion bodies.
- This sequence although it has homology with part of the lipoic acid binding domain of dihydrolipoamide acetyl transferases, has been genetically engineered to eliminate the possibility of modification by it and has the advantage of being poorly immunogenic.
- This procedure also includes the use of a monoclonal antibody that specifically recognizes said stabilizer, allowing immunodetection of any protein fused thereto.
- a recombinant plasmid is used as an expression vector, which carries said sequence under the control of the tryptophan (ptrip) promoter of E. coli, followed by Xbal, EcoRV and BamHI restriction sites that allow cloning into phase of DNA fragments encoding polypeptides of interest.
- This vector also includes terminator of transcription of gene 32 of bacteriophage T4, and of an ampicillin resistance gene as a selection marker.
- This procedure also makes possible the inclusion of the fusion polypeptide obtained in vaccine preparations intended for use in humans; and the nature of the stabilizing peptide used allows the generation of an effective immune response against the foreign protein or multi-epitope peptide bound thereto.
- the LpdA antigen of N. meningitidis is a 594 amino acid protein that belongs to the dihydrolipoamide dehydrogenase family (EC 1.8.1.4) and specifically, to a new subgroup within them characterized by having a domain of binding to lipoic acid, analogous to that present in dihydrolipoamide acetyl transferases, in its arninoterrninal portion (Kruger, N., Oppermann, FB, Lorenzl, H. and Steinbüchel, A., J. Bacteriol., 176, 3614-3630, 1994 ; Hein, S. and Steinbüchel, A., J. Bacteriol., 176, 4394-4408, 1994).
- the LpdA protein has been cloned and overexpressed in E. coli, with the addition of 5 amino acids (MLDKR) at its aminoterrninal end (European Patent Application No. 0 474 313 A2; Figure 1). Although the designations LpdA and P64k are equivalent, the name P64k will be used to refer to the recombinant protein.
- LpdA and P64k are equivalent, the name P64k will be used to refer to the recombinant protein.
- the epitopes for B cells present therein were located by evaluating the reactivity of an anti-P64k polyclonal serum. against synthetic peptides.
- P64k European Patent Application No. 0 474 313 A2 was purified by hydrophobicity chromatography in Butyl-TSK and gel filtration; and denatured by precipitating it with trichloroacetic acid (TCA), neutralizing with NaOH and equilibrating in phosphate buffer by gel filtration chromatography.
- TCA trichloroacetic acid
- This preparation was used to immunize 30 Balb / c mice with doses of 20 mg adjuvant with 2 mg of aluminum hydroxide subcutaneously, at 0, 7 and 21 days; and after 28 days the final extraction was done. The sera obtained were combined, and the resulting mixture was aliquoted and stored at -20 ° C.
- 59 peptides of 20 amino acids (a. A.) Were synthesized that cover the entire recombinant protein sequence and overlap by 10 a. a., using a set of reagents for solid phase synthesis (Multipin Peptide Synthesis System, Chairon Mimotope Pty., Ltd., USA) in 96-well plate format and following the manufacturer's instructions. These were numbered consecutively from the aminoterminal end of the protein. The reactivity of the antiP64k serum against these peptides was determined using a 1: 2000 dilution thereof, and the immunoassay format used was that recommended by the manufacturer of the above reagent kit.
- the expression vector pM-83 was constructed, into which it was introduced the coding sequence for a stabilizing peptide derived from the first 47 amino acids of said protein (NO. SEQUENCE IDENTIFICATION: 1). This sequence was cloned under the control of the tryptophan promoter of E. coli, this vector also presenting the terminator of the bacteriophage T4 as a signal of transcription termination and the ampicillin resistance gene as a selection marker.
- the stabilizer was first amplified using the Polymerase Chain Reaction (PCR) (Randall, K. et al, Science, 42394, 487-491, 1988) from plasmid pM-6, which carries the sequence nucleotide coding for the P64k antigen (European Patent Application No. 0 474 313 A2, Figure 1).
- PCR Polymerase Chain Reaction
- oligonucleotide primers 1573 and 1575 were used, which introduce Ncol and Xbal restriction sites in the amplified DNA fragment that correspond to the amino- and carboxyl-terminal ends of the stabilizer encoded therein:
- the amino acid sequence encoded by the resulting stabilizer is shown in Figure 3 (NO. SEQUENCE IDENTIFICATION: 6).
- the introduction of the Ncol restriction site exchanges Leucine 2 for a Valine; and primer 1575 removes the ETD sequence (position 45-47), introducing instead the DLE sequence.
- Lysic acid-binding Lysine position 48 is not part of the stabilizer, and its vicinity, which is highly conserved in these domains (Russell, GC, Guest, JR, Biochim. Biophys Acta, 1076, 225-232, 1991) is altered.
- Plasmid pM-83 was constructed by cloning this fragment (NO. SEQUENCE IDENTIFICATION: 5) previously digested Xbal / Ncol in plasmid pILM-29 (Guillen, G., Leal, M., Alvarez, A. et al , Biotechnology Act, 15, 97-106, 1995).
- PILM29 contains the gene for N. meningitidis Opc protein (5c) fused to a stabilizing peptide consisting of the first 58 amino acids of human IL-2, so that said cloning removes the IL-2 fragment and fuses the Opc to the stabilizer of the P64k ( Figure 4).
- the opc gene was in turn suppressed using the Xbal and BamHI enzymes and instead an adapter formed by the hybridization of oligonucleotides 1576 and 1577 was cloned, which introduces Xbal restriction sites, EcoRV and BamHI at the 3 'end of the stabilizer fragment:
- This plasmid was named pM-83 ( Figure 4).
- the similarity of the stabilizing peptide of pM-83 (EXAMPLE 2) with human proteins was determined by means of a homology search in the EMBL Data Library v.38 databases (Rice, CM, Fuchs, R., Higgins, DG et al, Nuc ⁇ Acids Res. 21, 2967-2971, 1993) of sequences nucleotides, and SWISS-PROT v.38 (Bairoch, A. and Boeckmann, B., Nuc ⁇ . Acids Res. 21, 3093-3096, 1993) of amino acid sequences; both versions of March 1994.
- BLASTP which compares an amino acid sequence against a protein sequence base (in this case SWISS-PROT)
- TBLASTN which compares an amino acid sequence against all translations in both directions and in all frames for reading a nucleotide sequence base, as in this case the EMBL Data Library
- a PAM120 valuation matrix was used [Dayhoff, MO, Schwartz, RM and Orcutt, BB, in: Dayhoff, MO (de.), Atlas of Protein Sequence and Structure, 5, Suppl. 3, 345-352, Natn Biomed.Res. Found., Washington, 1978].
- the ability of the stabilizer present in pM-83 to allow intracellular synthesis at high levels and in the form of inclusion bodies was evaluated by comparing the expression of several fused proteins to the first 22 or 58 amino acids of human Interleukin-2 (IL- 2), which is a fusion peptide widely used for this purpose, or fused to the first 47 aa of the modified P64k antigen as described in EXAMPLE 2.
- IL-2 human Interleukin-2
- the coding genes for the outer membrane proteins of N. meningitidis B: 4: P1.15 were cloned into the vectors pFP15 (hIL2-58; European Patent No. 416 673 Bl) or pM-83 (P64k-47).
- PorA and Opc in vectors pISL31 (hIL2-22, Castellanos-Serra, LR, Hardy, E., Ubieta, R., et al., Manuscript remitted) or pM-83, the genes coding for a multiepitopic polypeptide (PME) that includes immunogenic regions of various isolates of the Human Immunodeficiency Virus, HIV.
- the resulting expression plasmids are: pILM-28 (IL2-58 + PorA; Guillen, G., Alvarez, A., León, L., et al, 494-498 in: Conde-González, CJ, Morse, S. , Rice, P.
- pM-82 P64k-47 + PorA; Niebla, O., Alvarez, A ., González, S. et al, 85-86 in: Evans, JS, Yost, SE, Maiden, MCJ et al. (Eds.)., Neisseria 94: Proceedings of the IX International Pathogenic Neisseria Conference, Winchester, England, 1994), pILM-29 (IL2-58 + Opc; Guillen, G., Leal, M., Alvarez, A.
- the TAB4 and TAB9 proteins are multi-epitope polypeptides (PME) that include several copies of the central part of the variable region 3 (V3) of the HIV-1 gpl20 protein.
- PME multi-epitope polypeptides
- SRGIRIGPGRAILAT NO. I DENTI SEQUENCE FICATION: 9, -JY1: RQSTPIGLGQALYTT (NO. I DENTI SEQUENCE FICATION: 1 Q -RF: RKSITKGPGRVIYAT (NO. I DENT I SEQUENCE FICACON: 11) RKRIHIGPGRAFYTT (NO. I DENTI SEQUENCE FICATION: 12> -BRVA: RKRITMGPGRVYYTT (NO. I DENTI SEQUENCE FICATION: 13 - II IB: SIRIQRGPGRAFVTI (NO.
- pTAB3 From the resulting plasmid, called pTAB3, a fragment containing the gene for PME, tryptophan promoter and phage T4 terminator was extracted by digestion with the enzymes Seal and HindIII, and cloned into pUC19 (Yanisch-Perron, C. et al ., 1985, Gene 33, 103-1 19) to obtain pTAB4 ( Figure 7).
- pTAB9 was constructed by eliminating the coding sequence for the stabilizer derived from human IL-2 by digestion with the Ncol and Xbal enzymes, and cloning instead a fragment encoding the first 47 amino acids of the P64k antigen obtained by Chain Reaction Polymerase (PCR), as described in EXAMPLE 2.
- PCR Chain Reaction Polymerase
- the E. coli K-12 host strains used for all these plasmids were W31 10 (Hill, CW, and Hamish, B, W. Proc.Natl. Acad. Sci., 78, 7069, 1981; Jensen, KF, J.Bacteriol., 175, 3401-3407, 1993) for pILM-28, pILM-29, pM-80 and pM-82; and W3110 trpA905, for pTAB4 and pTAB9.
- Said culture was used to inoculate cultures of 50 mL of LB-Ap (pTAB4 and pTAB9) or of a defined medium composed of M9 salts (Miller, JH, Experiment in Molecular Genetics, Cold Spring Harbor Laboratory Press, 1972, New York, USA ), 1% glucose, 1% casein hydrolyzate, 0.1 mM CaCi2, lmM MgCb and Ap at 50 ug / mL ( ⁇ ILM-28, pILM-29, pM-80, pM-82), which grew 12 at 37 ° C and 250 rpm After this time, total protein samples were taken and analyzed by denaturing electrophoresis in polyacrylamide gels (SDS-PAGE, Laemmli, UK, Nature, 277, 680, 1970) and bright blue staining of Coomassie R-250; analyzing the percent of expression with a Bromma-LKB laser densitometer.
- M9 salts M9 salt
- Protein insolubility was used as a criterion to assume its expression as inclusion bodies, since other conditions under which it can exhibit such behavior (association with membranes or peptidoglycan) are unlikely in this case.
- a ligand that specifically recognizes the stabilizer is a desirable feature in any expression system of recombinant proteins. This is because the above may allow, for example, the design of efficient affinity purification schemes if said ligand is immobilized in a chromatographic resin; and even - in the case of antibodies - monitoring the intermediate steps of purification by immunological techniques, regardless of the identity of the expressed heterologous protein.
- TAB13 is a PME derived from
- -C6 TSITIGPGQVFYRTG (NO. SEQUENCE IDENTIFICATION: 15)
- -C8 RQRTSIGQGQALYTT (NO. SEQUENCE IDENTIFICATION: 16)
- mice were immunized subcutaneously with 3 doses of 20 ⁇ g of TAB13 adjuvant in Al (OH) 3 with a 15 day interval; and an intraperitoneal reactivation with 20 ⁇ g of TAB13 in phosphate buffer, 20 days after the last dose.
- Splecnocytes of this animal were fused with myeloma X63 Ag8 653 and the resulting hybridomas were isolated and investigated according to established methods (Gavilondo, JV (ed.), Monoclonal Antibodies: Theory and Practice, Elfos Scientiae, 1995, Havana, Cuba) .
- the reactivity of the antibodies secreted by the isolated hybridomas was evaluated by ELISA, coating with the PME TAB13, the P64k protein or synthetic peptides representing the different V3 regions present in TAB13. In total, 18 positive clones were obtained, one of which, called 448/30/7, recognizes both TAB13 and P64k, but none of the gpl20 peptides.
- coli strain MM294 (Sambrook, J., Fritsch, EF and Maniatis, T., Molecular Cloning: A Laboratory Manual, 1989, Cold Spring Harbor Laboratory Press, New York, USA) was transformed with the following plasmids: pILM-28 (IL2-58 + porA), pM-82 (P64k-47 + porA), pTAB13 (P64k-47 + PME), pM-6 (P64k) and pFP15 (IL-2).
- the expression plasmid pM-134 was also used, which contains the first 120 amino acids of P64k (which comprise the lipoic acid binding site) under identical regulatory signals as above. This segment was amplified by PCR using primers Nos. 1573 (NO.
- SEQUENCE IDENTIFICATION 2) and 2192 (NO. SEQUENCE IDENTIFICATION: 4); it was digested with the enzymes Ncol and BamHI, and cloned into plasmid pFP15 (See EXAMPLE 4) digested identically. The expression of these transformants was achieved under the growth conditions specified in EXAMPLE 4 for pTAB4 and pTAB9.
- the expression system formed by the P64k-47 stabilizer, the plasmids that contain it and the MAb 448/30/7 allows the efficient synthesis and in the form of inclusion bodies of a large variety of proteins, and their detection without the previous availability of immunological probes against each polypeptide to be expressed.
- EXAMPLE 6 The absence of deleterious effects on the immune response against the polypeptide fused to the stabilizer is an important factor to consider when selecting an expression system for vaccine candidates.
- One of the advantages of the expression system based on the P64k-47 stabilizer is precisely its low immunogenicity (EXAMPLE 1), which guarantees the above.
- the influence of the P64k-47 stabilizer on the immune response against the fused protein was assessed qualitatively by WO 97/26359 ⁇ '
- biomass was obtained from strains W31 10 trpA905 + pTAB4 and W3110 trpA905 + pTAB9 as described in EXAMPLE 4. This biomass was broken by combining the treatment with lysozyme and with ultrasound in the presence of phenylmethyl sulfonyl fluoride (PMSF) and the non-ionic detergent Triton-X-100; the inclusion bodies were obtained by differential centrifugation, and the PMEs were partially purified and solubilized by two successive cycles of washing the inclusion bodies with 0 chaotropic agents and detergents (TAB4: 1. Urea 4 M + Triton-X-100 1 %, 2.
- PMSF phenylmethyl sulfonyl fluoride
- Titres were calculated as the maximum dilution of each serum with an absorbance value greater than double that of a mixture of preimmune sera; All sera were analyzed in duplicate.
- Figure 1 Nucleotide sequence of the P64k gene. The sequence added in plasmid pM-6 is shown in italics (European Patent Application No. 0 474 313 A2), originally absent in the IpdA gene.
- Figure 2 Polyclonal mouse serum reactivity against P64k peptides. A minimum value of 0.4 optical density units was chosen to consider the result as positive.
- Figure 3 Stabilized amino acid sequence, deduced from the DNA sequence amplified by PCR from plasmid pM-6. The underlined sequences correspond to the oligonucleotide primers.
- Figure 4 Construction strategy of plasmid pM-83.
- Figure 5 Results of the homology search between the stabilizer sequences ('Query') and those present in the SWISS-PROT ('Sbjct') base, using the BLASTP program. Only entries corresponding to human or mammalian proteins are shown.
- P (N) represents the probability of finding N equal alignments on a base composed of random sequences; the significance of homology decreases with the value of P (N). Identical waste is represented by its one letter code; Conservative substitutions with a '+', and differences are not noted.
- Figure 6 Results of the homology search between the stabilizer sequences ('Query') and all possible translations of the sequences of the EMBL Data Library ('Sbjct'), using the TBLASTN program. Only entries corresponding to human or mammalian proteins are shown.
- P (N) represents the probability of finding N equal alignments on a base composed of random sequences; the significance of homology decreases with the value of P (N). Identical waste is represented by its one letter code; Conservative substitutions with a '+', and differences are not noted.
- Figure 7 Construction strategy of pTAB4 and pTAB9.
- Figure 8 Nucleotide and amino acid sequence of PME TAB9.
- Figure 9 A: General structure of PME TAB4 and TAB9.
- B General structure of the PME TAB13.
- Figure 10 Comparison- of the expression of the porA, opc and PME genes under stabilizers derived from human IL-2 or the first 47 amino acids of the P64k antigen.
- hIL2-58 refers to the first 58 amino acids of human IL-2, hIL2-22 to the first 22, and P64k-47 to the stabilizer derived from the first 47 amino acids of the P64k antigen.
- B Analysis compared by SDS-PAGE of PME expression in plasmids TAB4 and TAB9.
- Lane A Molecular weight markers; B: Total proteins of strain W3110 trpA905; C: Total proteins of W3J 10 trpA905 + pTAB4; D: purified TAB4; E: Total W31 10 trpA905 + pTAB9 proteins; F:
- TAB9 Expression of TAB9 in inclusion bodies.
- A Soluble proteins of the sample.
- B Insoluble or membrane proteins.
- Figure 11 Western blotting 'using MAb 448/30/7 with samples of total E. coli MM294 proteins transformed with: 1: Negative control, 2: pM-6 (P64k), 3: pM-82 (P64k-47 + by A), 4: pTAB13 (P64k-47 + PME), 5: pFP15
- IL-2 IL-2
- 6 pM-134 (P64k-120)
- 7 pILM-28 (IL2-58 + porA).
- the migration of molecular weight patterns is represented on the left.
- Figure 12 Reciprocal of the ELISA titre value of rabbits immunized with TAB4 and TAB9.
- MG Geometric mean of the reciprocal of the anti V3 titles; A: Percentage of reactivity with V3 peptides.
- TYPE OF MOLECULE First 47 amino acids of the recombinant protein P64k of N. menmgi tidis.
- PROPERTIES Primer 5 'No. 1573 for PCR amplification of the first 44 amino acids of the P64k antigen of N. memngi tidis.
- PROPERTIES 3 'No. 1575 primer for PCR amplification of the first 44 amino acids of the P64k antigen of N. meningi tidis.
- PROPERTIES 3 'No. 2192 primer for PCR amplification of the first 120 amino acids of the P64k antigen of N. menmgi tidis.
- PROPERTIES Derived from the first 47 amino acids of the antigen
- TYPE OF MOLECULE Stabilizer derived from the first 47 amino acids of the P64k antigen from Neisse ⁇ a meningi tidis
- PROPERTIES It has the following changes with respect to P64K: L2 ⁇ V2;
- TYPE OF MOLECULE Synthetic oligonucleotide.
- TYPE OF MOLECULE Central region of the V3 loop of HIV-1 gpl20, LR150 isolation
- TYPE OF MOLECULE Central region of the V3 loop of HIV-1 gpl20, JY1 isolation.
- TYPE OF MOLECULE Central V3 loop region of HIV-1 gpl20, RF isolation.
- TYPE OF MOLECULE Central region of the V3 loop of HIV-1 gpl20, MN isolation.
- TYPE OF MOLECULE Central region of the V3 loop of HIV-1 gpl20, BRVA isolation.
- TYPE OF MOLECULE Central region of the V3 loop of HIV-1 gpl20, IIIB isolation.
- TYPE OF MOLECULE Consensus sequence of the central region of the V3 loop of the gpl20 of different HIV-1 isolates, position within the PME TAB13.
- V3 of the gpl20 of different isolates of HIV-1 position 8 within the PME TAB13.
- TYPE OF MOLECULE Flexible spacer that separates epitopes V3 in PME TAB3, TAB4, TAB9 and TAB13
- PROPERTIES Encodes for V3 epitopes linked by the spacer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP52556497A JP4071282B2 (ja) | 1996-01-17 | 1997-01-17 | 融合タンパク質としての異種抗原の発現系 |
US08/930,917 US6146635A (en) | 1996-01-17 | 1997-01-17 | System for the expression of heterologous antigens as fusion proteins |
AT97901516T ATE198491T1 (de) | 1996-01-17 | 1997-01-17 | System zur expression von heterologen antigenen als fusionsproteine |
AU15396/97A AU722317B2 (en) | 1996-01-17 | 1997-01-17 | Expression system of heterologous antigens as fusion proteins |
DK97901516T DK0816506T3 (da) | 1996-01-17 | 1997-01-17 | System til ekspression af heterologe antigener som fusionsproteiner |
BRPI9704641-8A BR9704641B1 (pt) | 1996-01-17 | 1997-01-17 | proteìna de fusão, vetor de expressão de proteìnas de fusão em e. coli, cepa recombinante e composição de vacina. |
EP97901516A EP0816506B1 (en) | 1996-01-17 | 1997-01-17 | System for the expression of heterologous antigens as fusion proteins |
EA199700244A EA000307B1 (ru) | 1996-01-17 | 1997-01-17 | СЛИТЫЙ БЕЛОК, ВЕКТОР ЭКСПРЕССИИ СЛИТОГО БЕЛКА, РЕКОМБИНАНТНЫЙ ШТАММ БАКТЕРИЙ Escherichia coli И ВАКЦИННЫЙ ПРЕПАРАТ |
DE69703813T DE69703813T2 (de) | 1996-01-17 | 1997-01-17 | System zur expression von heterologen antigenen als fusionsproteine |
IL121614A IL121614A (en) | 1996-01-17 | 1997-01-17 | Fusion proteins that contain a stabilizing peptide that binds to a protein |
MX9707071A MX9707071A (es) | 1996-01-17 | 1997-01-17 | Sistema de expresion de antigenos heterologos como proteinas de fusion. |
KR1019970706451A KR100500782B1 (ko) | 1996-01-17 | 1997-01-17 | 융합단백질로서의 이종성 항원유전자 발현 시스템 |
US09/612,925 US6921809B1 (en) | 1996-01-17 | 2000-07-10 | Monoclonal antibody to the stabilizer peptide of the P64K antigen of Neisseria meningitidis |
GR20010400539T GR3035690T3 (en) | 1996-01-17 | 2001-04-02 | System for the expression of heterologous antigens as fusion proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU10/96 | 1996-01-17 | ||
CU1996010A CU22559A1 (es) | 1996-01-17 | 1996-01-17 | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/930,917 A-371-Of-International US6146635A (en) | 1996-01-17 | 1997-01-17 | System for the expression of heterologous antigens as fusion proteins |
US09/612,925 Division US6921809B1 (en) | 1996-01-17 | 2000-07-10 | Monoclonal antibody to the stabilizer peptide of the P64K antigen of Neisseria meningitidis |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997026359A1 true WO1997026359A1 (es) | 1997-07-24 |
Family
ID=5459182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU1997/000001 WO1997026359A1 (es) | 1996-01-17 | 1997-01-17 | Sistema de expresion de antigenos heterologos como proteinas de fusion |
Country Status (22)
Country | Link |
---|---|
US (2) | US6146635A (es) |
EP (1) | EP0816506B1 (es) |
JP (1) | JP4071282B2 (es) |
KR (1) | KR100500782B1 (es) |
CN (1) | CN1107115C (es) |
AR (1) | AR005651A1 (es) |
AT (1) | ATE198491T1 (es) |
AU (1) | AU722317B2 (es) |
BR (1) | BR9704641B1 (es) |
CA (1) | CA2214840A1 (es) |
CU (1) | CU22559A1 (es) |
CZ (1) | CZ291097A3 (es) |
DE (1) | DE69703813T2 (es) |
DK (1) | DK0816506T3 (es) |
EA (1) | EA000307B1 (es) |
ES (1) | ES2157060T3 (es) |
GR (1) | GR3035690T3 (es) |
HU (1) | HUP9800730A3 (es) |
IL (1) | IL121614A (es) |
MX (1) | MX9707071A (es) |
PT (1) | PT816506E (es) |
WO (1) | WO1997026359A1 (es) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999055873A2 (en) * | 1998-04-24 | 1999-11-04 | Smithkline Beecham Biologicals S.A. | Basb006 polynucleotide(s) and polypeptides from neisseria meningitis |
WO1999058683A2 (en) * | 1998-05-13 | 1999-11-18 | Smithkline Beecham Biologicals S.A. | BASB029 POLYNUCLEOTIDE(S) AND POLYPEPTIDES FROM $i(NEISSERIA MENINGITIDIS) |
WO2000011182A1 (en) * | 1998-08-18 | 2000-03-02 | Smithkline Beecham Biologicals S.A. | Basb024 outer membrane protein of neisseria meningitidis |
WO2003008571A2 (es) * | 2001-07-16 | 2003-01-30 | Centro De Ingenieria Genetica Y Biotecnologia | Cadenas quiméricas codificantes para proteínas inductoras de efectos contra virus |
US7491528B2 (en) * | 2001-08-14 | 2009-02-17 | Korea Advanced Institute Of Science And Technology | Method for extracellular production of target proteins employing OmpF in E. coli |
US7714121B2 (en) | 1998-01-14 | 2010-05-11 | Novartis Vaccines And Diagnostics Srl | Meningococcal antigens |
US7790173B2 (en) | 2005-09-16 | 2010-09-07 | Centro De Ingenieria Genetica Y Biotecnologia | Pharmaceutical compound capable of induce immune protective response against Dengue virus having the capsid protein of the Dengue virus |
US8034358B2 (en) | 1997-12-12 | 2011-10-11 | The University of Queesland | Surface antigen |
US8674063B2 (en) | 2006-10-30 | 2014-03-18 | Centro De Ingenieria Genetica Y Biotecnologia | Chimerical peptidic molecules with antiviral properties against the viruses of the Flaviviridae family |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1141313A2 (en) * | 1998-12-31 | 2001-10-10 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
WO2000039303A2 (en) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Modified hiv env polypeptides |
US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
AUPQ347199A0 (en) * | 1999-10-15 | 1999-11-11 | Csl Limited | Novel polypeptide fragments |
CA2415923C (en) | 2000-07-12 | 2011-10-25 | Agensys, Inc. | Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
EP1313850B1 (en) | 2000-08-28 | 2008-08-06 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer |
US6924358B2 (en) | 2001-03-05 | 2005-08-02 | Agensys, Inc. | 121P1F1: a tissue specific protein highly expressed in various cancers |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
CA2443123A1 (en) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
US20030191073A1 (en) | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
EP2292772A1 (en) * | 2001-07-05 | 2011-03-09 | Novartis Vaccines and Diagnostics, Inc. | HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide |
AU2002320314A1 (en) * | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
WO2003020876A2 (en) | 2001-08-31 | 2003-03-13 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
ES2532757T3 (es) | 2001-09-06 | 2015-03-31 | Agensys, Inc. | Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer |
MX339524B (es) * | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
US20040081653A1 (en) | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
AU2002352976B2 (en) | 2002-11-27 | 2007-11-08 | Agensys, Inc. | Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
WO2004072263A2 (en) | 2003-02-10 | 2004-08-26 | Agensys, Inc. | Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
PT1629088E (pt) | 2003-05-30 | 2012-04-10 | Agensys Inc | Variantes de antigénio de células estaminais de próstata (psca) e subsequências das mesmas |
US20050040037A1 (en) * | 2003-08-20 | 2005-02-24 | Walton Scott G. | Electron beam enhanced large area deposition system |
CU23237A1 (es) * | 2003-12-03 | 2007-09-26 | Ct Ingenieria Genetica Biotech | PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS |
CU23236A1 (es) * | 2003-12-03 | 2007-09-26 | Ct Ingenieria Genetica Biotech | PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P |
MXPA06013834A (es) | 2004-05-28 | 2007-03-01 | Agensys Inc | Anticuerpos y moleculas relacionadas que enlazan a proteinas psca. |
CN100518818C (zh) * | 2004-11-15 | 2009-07-29 | 中国人民解放军军事医学科学院生物工程研究所 | 一种预防和/或治疗消化系统肿瘤的疫苗 |
RU2413735C2 (ru) | 2005-03-31 | 2011-03-10 | Эдженсис, Инк. | Антитела и родственные молекулы, связывающиеся с белками 161p2f10b |
US20110110974A1 (en) * | 2007-10-29 | 2011-05-12 | Erik Depla | Methods and kits for inducing a ctl response using a prime boost regimen |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
EP2530159A1 (en) * | 2011-06-03 | 2012-12-05 | Sandoz Ag | Transcription terminator sequences |
PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
CU20200075A7 (es) | 2020-10-22 | 2022-05-11 | Ct Ingenieria Genetica Biotecnologia | Antígeno quimérico que comprende el dominio extracelular de pd-l1 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014431A1 (en) * | 1989-05-19 | 1990-11-29 | Biotechnology Research And Development Corporation | Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification |
EP0474313A2 (en) * | 1990-09-07 | 1992-03-11 | Centro De Ingenieria Genetica Y Biotecnologia | Nucleotide sequence coding for an outer membrane protein from Neisseria meningitidis and use of said protein in vaccine preparations |
-
1996
- 1996-01-17 CU CU1996010A patent/CU22559A1/es not_active IP Right Cessation
-
1997
- 1997-01-17 DE DE69703813T patent/DE69703813T2/de not_active Expired - Fee Related
- 1997-01-17 AT AT97901516T patent/ATE198491T1/de not_active IP Right Cessation
- 1997-01-17 HU HU9800730A patent/HUP9800730A3/hu unknown
- 1997-01-17 PT PT97901516T patent/PT816506E/pt unknown
- 1997-01-17 EP EP97901516A patent/EP0816506B1/en not_active Expired - Lifetime
- 1997-01-17 US US08/930,917 patent/US6146635A/en not_active Expired - Fee Related
- 1997-01-17 AU AU15396/97A patent/AU722317B2/en not_active Ceased
- 1997-01-17 CZ CZ972910A patent/CZ291097A3/cs unknown
- 1997-01-17 JP JP52556497A patent/JP4071282B2/ja not_active Expired - Fee Related
- 1997-01-17 KR KR1019970706451A patent/KR100500782B1/ko not_active IP Right Cessation
- 1997-01-17 IL IL121614A patent/IL121614A/en not_active IP Right Cessation
- 1997-01-17 BR BRPI9704641-8A patent/BR9704641B1/pt not_active IP Right Cessation
- 1997-01-17 MX MX9707071A patent/MX9707071A/es not_active IP Right Cessation
- 1997-01-17 EA EA199700244A patent/EA000307B1/ru not_active IP Right Cessation
- 1997-01-17 ES ES97901516T patent/ES2157060T3/es not_active Expired - Lifetime
- 1997-01-17 DK DK97901516T patent/DK0816506T3/da active
- 1997-01-17 CA CA002214840A patent/CA2214840A1/en not_active Abandoned
- 1997-01-17 WO PCT/CU1997/000001 patent/WO1997026359A1/es not_active Application Discontinuation
- 1997-01-17 AR ARP970100192A patent/AR005651A1/es active IP Right Grant
- 1997-01-17 CN CN97190017A patent/CN1107115C/zh not_active Expired - Fee Related
-
2000
- 2000-07-10 US US09/612,925 patent/US6921809B1/en not_active Expired - Fee Related
-
2001
- 2001-04-02 GR GR20010400539T patent/GR3035690T3/el not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014431A1 (en) * | 1989-05-19 | 1990-11-29 | Biotechnology Research And Development Corporation | Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification |
EP0474313A2 (en) * | 1990-09-07 | 1992-03-11 | Centro De Ingenieria Genetica Y Biotecnologia | Nucleotide sequence coding for an outer membrane protein from Neisseria meningitidis and use of said protein in vaccine preparations |
Non-Patent Citations (2)
Title |
---|
BRINGAS R ET AL: "A Lipoamide Dehydrogenase From Neisseria meningitidis has a Lipoyl Domain.", PROTEINS STRUCTURE FUNCTION AND GENETICS 21 (4). 1995. 303-306. ISSN: 0887-3585, XP000671539 * |
GERARDO GUILLÉN ET AL.: "Cloning, expression and characterization of the P64k outer membrane protein from N. meningitidis", BIOTECNOLOGÍA APLICADA, vol. 12, no. 2, 1995, pages 72, XP000671542 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8067004B2 (en) | 1997-12-12 | 2011-11-29 | The University Of Queensland | Surface antigen |
US8034358B2 (en) | 1997-12-12 | 2011-10-11 | The University of Queesland | Surface antigen |
US7714121B2 (en) | 1998-01-14 | 2010-05-11 | Novartis Vaccines And Diagnostics Srl | Meningococcal antigens |
WO1999055873A3 (en) * | 1998-04-24 | 2000-03-09 | Smithkline Beecham Biolog | Basb006 polynucleotide(s) and polypeptides from neisseria meningitis |
WO1999055873A2 (en) * | 1998-04-24 | 1999-11-04 | Smithkline Beecham Biologicals S.A. | Basb006 polynucleotide(s) and polypeptides from neisseria meningitis |
US6696062B1 (en) | 1998-04-24 | 2004-02-24 | Smithkline Beecham Biologicals S.A. | BASB006 polypeptides from Neisseria meningitidis and immunogenic compositions thereof |
US7419824B2 (en) | 1998-04-24 | 2008-09-02 | Glaxosmithkline Biologicals, S.A,. | BASB006 polypeptides from Neisseria meningitidis and immunogenic compositions thereof |
EP1621623A3 (en) * | 1998-05-13 | 2009-02-18 | Glaxosmithkline Biologicals S.A. | Basb029polynucleotide(s) and polypeptides from neisseria meningitis |
WO1999058683A2 (en) * | 1998-05-13 | 1999-11-18 | Smithkline Beecham Biologicals S.A. | BASB029 POLYNUCLEOTIDE(S) AND POLYPEPTIDES FROM $i(NEISSERIA MENINGITIDIS) |
WO1999058683A3 (en) * | 1998-05-13 | 2000-04-06 | Smithkline Beecham Biolog | BASB029 POLYNUCLEOTIDE(S) AND POLYPEPTIDES FROM $i(NEISSERIA MENINGITIDIS) |
US6780419B1 (en) | 1998-05-13 | 2004-08-24 | Glaxosmithkline Biologicals S.A. | Basb029 polynucleotide(s) and polypeptides from neisseria meningitidis |
WO2000011182A1 (en) * | 1998-08-18 | 2000-03-02 | Smithkline Beecham Biologicals S.A. | Basb024 outer membrane protein of neisseria meningitidis |
WO2003008571A2 (es) * | 2001-07-16 | 2003-01-30 | Centro De Ingenieria Genetica Y Biotecnologia | Cadenas quiméricas codificantes para proteínas inductoras de efectos contra virus |
US7566457B2 (en) | 2001-07-16 | 2009-07-28 | Centro De Ingeniera Genetica Y Biotecnologia | Chimeric proteins that induce effects directed against viruses |
CN100378123C (zh) * | 2001-07-16 | 2008-04-02 | 遗传工程与生物技术中心 | 编码可诱导抗病毒效应的蛋白质的嵌合链 |
KR100991717B1 (ko) | 2001-07-16 | 2010-11-03 | 인스티튜토 데 메디시나 트로피칼 〃페드로 쿠리〃 | 바이러스에 대한 효과를 유도하는 단백질을 코딩하는키메라 사슬 |
US7947281B2 (en) | 2001-07-16 | 2011-05-24 | Centro De Ingenieria Genetica Y Biotechnologia | Chimeric proteins that induce effects directed against viruses |
US7279164B2 (en) | 2001-07-16 | 2007-10-09 | Centro De Ingenieria Genetica Y Biotecnologia | Chimeric proteins that induce effects directed against viruses |
WO2003008571A3 (es) * | 2001-07-16 | 2004-03-04 | Ct Ingenieria Genetica Biotech | Cadenas quiméricas codificantes para proteínas inductoras de efectos contra virus |
US8105606B2 (en) | 2001-07-16 | 2012-01-31 | Centro De Ingenieria Genetica Y Biotecnologia | Chimeric proteins that induce effects directed against viruses |
US7491528B2 (en) * | 2001-08-14 | 2009-02-17 | Korea Advanced Institute Of Science And Technology | Method for extracellular production of target proteins employing OmpF in E. coli |
US7790173B2 (en) | 2005-09-16 | 2010-09-07 | Centro De Ingenieria Genetica Y Biotecnologia | Pharmaceutical compound capable of induce immune protective response against Dengue virus having the capsid protein of the Dengue virus |
US8674063B2 (en) | 2006-10-30 | 2014-03-18 | Centro De Ingenieria Genetica Y Biotecnologia | Chimerical peptidic molecules with antiviral properties against the viruses of the Flaviviridae family |
Also Published As
Publication number | Publication date |
---|---|
CN1107115C (zh) | 2003-04-30 |
DK0816506T3 (da) | 2001-05-21 |
KR100500782B1 (ko) | 2005-11-25 |
JP4071282B2 (ja) | 2008-04-02 |
CU22559A1 (es) | 1999-05-03 |
EP0816506A1 (en) | 1998-01-07 |
EA199700244A1 (ru) | 1998-02-26 |
BR9704641B1 (pt) | 2010-03-09 |
AU1539697A (en) | 1997-08-11 |
ATE198491T1 (de) | 2001-01-15 |
AU722317B2 (en) | 2000-07-27 |
PT816506E (pt) | 2001-06-29 |
AR005651A1 (es) | 1999-07-14 |
EA000307B1 (ru) | 1999-04-29 |
KR19980703043A (ko) | 1998-09-05 |
IL121614A0 (en) | 1998-02-08 |
DE69703813T2 (de) | 2001-08-09 |
EP0816506B1 (en) | 2001-01-03 |
HUP9800730A2 (hu) | 1998-07-28 |
ES2157060T3 (es) | 2001-08-01 |
US6921809B1 (en) | 2005-07-26 |
CN1177982A (zh) | 1998-04-01 |
CZ291097A3 (cs) | 1998-11-11 |
HUP9800730A3 (en) | 1999-07-28 |
CA2214840A1 (en) | 1997-07-24 |
MX9707071A (es) | 1997-11-29 |
US6146635A (en) | 2000-11-14 |
BR9704641A (pt) | 1998-06-09 |
DE69703813D1 (de) | 2001-02-08 |
IL121614A (en) | 2006-10-31 |
GR3035690T3 (en) | 2001-07-31 |
JPH11503617A (ja) | 1999-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997026359A1 (es) | Sistema de expresion de antigenos heterologos como proteinas de fusion | |
JP3658690B2 (ja) | ウイルスの膜蛋白質の天然ドメインの獲得方法、特にhivに対するワクチンとしてのそれらの使用 | |
EP0759941B1 (en) | Heterodimer polypeptideimmunogen carrier composition and method for their use | |
JP2003529319A (ja) | HIV−1gp41を標的化する広範に中和する抗体を誘発する方法 | |
EP2237794B1 (en) | Chimeric hiv fusion proteins as vaccines | |
JP2023540486A (ja) | 免疫原性コロナウイルス融合タンパク質および関連方法 | |
EP0519986A1 (en) | Synthetic polypeptides | |
JP2887238B2 (ja) | ポリペプチド | |
US8961987B2 (en) | Immunogen comprising the HIV GP120 V3 loop in a conformation that induces broadly neutralizing antibodies | |
JP2974348B2 (ja) | ヘモフイルス インフルエンザb型の膜タンパク及びペプチド | |
JP4768944B2 (ja) | 組換え型の治療的融合タンパク | |
ES2260416T3 (es) | Polipeptido que induce anticuerpos que neutralizan el vih. | |
EP2265632B1 (en) | Cd4-related polypeptides and methods of use | |
Kolli et al. | A synthetic dengue virus antigen elicits enhanced antibody titers when linked to, but not mixed with, Mycobacterium tuberculosis HSP70 domain II | |
Quintana et al. | Antibody response in rabbits against two HIV-1 multi-epitope polypeptides bearing different copies of V3 epitopes fused to the N terminal fragment of N. meningitidis P64K protein | |
JP2022116482A (ja) | SARS-CoV-2由来のアミノ酸配列およびその利用 | |
EP0588750A2 (en) | Method for the production of recombinant polypeptides bearing epitopes from different hiv isolates, and their uses as immunogens and in the detection of antibodies against hiv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97190017.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CZ HU IL JP KR MX SI US AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2214840 Country of ref document: CA Ref document number: 2214840 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970706451 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997901516 Country of ref document: EP Ref document number: PV1997-2910 Country of ref document: CZ Ref document number: 08930917 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 1997 525564 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 199700244 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1997901516 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970706451 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-2910 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997901516 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019970706451 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1997-2910 Country of ref document: CZ |